What Is Stage 0 Cancer and How Is It Treated?

Stage 0 cancer describes abnormal cells that are confined to the tissue layer where they first formed and have not invaded deeper structures or spread to nearby lymph nodes. Doctors call this “carcinoma in situ,” which literally means “cancer in place.” Because these cells haven’t crossed the basement membrane separating one tissue type from another, stage 0 is considered preinvasive, and outcomes after treatment are overwhelmingly favorable. Yet the label can be misleading: the word “cancer” triggers alarm, while the biology behind stage 0 often behaves nothing like the invasive disease most people picture. How aggressively it should be treated, and whether some cases need treatment at all, remains one of the more active debates in oncology.

What “In Situ” Actually Means

The staging system most widely used in the United States and internationally is maintained by the American Joint Committee on Cancer (AJCC). It classifies tumors based on the size of the primary tumor, whether lymph nodes are involved, and whether the cancer has metastasized. Stage 0 sits at the very bottom of this scale: the abnormal cells are present but have not grown beyond their original layer.¹ In a breast duct, for example, the cells line the inside of the duct but haven’t pushed through its wall. In skin, they sit within the epidermis but haven’t reached the dermis below. This distinction matters enormously because once cells cross that boundary, they gain access to blood vessels and lymphatic channels, which is how cancers spread to distant organs.

Not every organ site uses “stage 0” in exactly the same way, but the underlying principle is consistent: the cells look abnormal under a microscope and may have the genetic features of cancer, yet they remain physically contained. The most common stage 0 diagnoses involve the breast, skin, cervix, bladder, and colon.

Stage 0 Breast Cancer (DCIS)

Ductal carcinoma in situ, or DCIS, is by far the most frequently diagnosed stage 0 cancer. It consists of abnormal cells confined to the milk ducts of the breast and nearly always shows up in women who have no symptoms, found only because a screening mammogram detected suspicious calcifications.² The rise of routine mammography transformed DCIS from a rare finding into a common one: incidence climbed from fewer than 2 per 100,000 women in the early 1970s to roughly 33 per 100,000 by 2005, with the largest increases in women over 50.³

Mammography detects DCIS primarily through characteristic calcification patterns, and it does so with reasonable sensitivity. When researchers have compared imaging methods head to head, MRI has shown significantly higher sensitivity for DCIS than mammography alone. In one study, MRI detected DCIS in about 88% of affected breasts compared with 27% for mammography.⁴ Still, mammography remains the primary screening tool for most women because MRI is expensive, less widely available, and produces more false positives. MRI tends to be reserved for women at higher risk or those with dense breast tissue where mammography struggles.

How DCIS Is Treated

Standard treatment for DCIS involves surgery, often followed by radiation and sometimes hormonal therapy. The goal is to remove the abnormal cells and reduce the chance they will return or progress to invasive cancer. Most women undergo a lumpectomy (breast-conserving surgery), though some opt for mastectomy depending on the extent of the disease or personal preference.

Radiation after lumpectomy cuts the risk of recurrence substantially. A large randomized trial following women for over a decade found that radiotherapy reduced the incidence of all new breast events by about 60%, including a roughly 70% reduction in invasive cancer developing on the same side.⁵ The same trial showed that tamoxifen, a hormonal drug, reduced overall breast events by about 30% and cut the rate of cancer developing in the opposite breast by more than half. However, tamoxifen did not reduce the risk of invasive cancer on the treated side.

For postmenopausal women with hormone-receptor-positive DCIS, the choice between tamoxifen and anastrozole (an aromatase inhibitor) has been studied directly. Anastrozole showed a modest advantage overall, but the benefit was driven almost entirely by women younger than 60. For women 60 and older, the two drugs performed similarly, so the decision often comes down to side-effect profiles. Tamoxifen carries a higher risk of blood clots, while anastrozole is associated with joint pain and bone thinning.⁶ Quality-of-life research on these same patients reinforced that tolerability matters: if side effects from one drug become intolerable, switching to the other remains a reasonable alternative.⁷

Melanoma In Situ

Melanoma in situ is another common stage 0 diagnosis. Here, the abnormal melanocytes (pigment-producing cells) sit entirely within the epidermis, the outermost layer of skin. Treatment is surgical excision, and the critical question is how wide the margins need to be to ensure all abnormal cells are removed.

This turns out to be less straightforward than it sounds. For small, well-defined lesions on the trunk, a 5-millimeter margin around the visible lesion often achieves clearance.⁸ But many melanomas in situ are not small or well-defined. One study found that the commonly recommended 5-millimeter margin is inadequate for many cases and proposed that 9 millimeters of normal-appearing skin should be the standard.⁹ Lesions on the head and neck are particularly tricky because the abnormal cells tend to extend further than the eye can see. A 10-year review of Mohs surgery (a technique that examines tissue layer by layer during the procedure) found that only 62% of head and neck melanoma in situ cases were cleared with 5-millimeter margins; it took 15 millimeters to reach a 97% clearance rate.¹⁰ Larger tumors and certain locations like the cheek correlated with needing wider margins.

Because the face and scalp are cosmetically sensitive areas, this creates a genuine tension between removing enough tissue to be safe and preserving appearance and function. Mohs surgery helps resolve this by mapping the tumor’s edges in real time, but it is more time-consuming and requires specialized training.

Cervical and Bladder Carcinoma In Situ

The cervix and bladder represent two other sites where stage 0 cancer is commonly identified, though the treatments look quite different from one another.

Cervical carcinoma in situ (historically called CIN III) is usually found through Pap smears and HPV testing. Treatment typically involves a loop electrosurgical excision procedure (LEEP), which removes the abnormal tissue using a thin heated wire. The procedure is effective, but certain factors raise the risk of the abnormality persisting or returning: age 55 and older, HIV infection, and having a positive margin at the inner edge of the removed tissue.¹¹ Menopausal status is another independent predictor of positive margins after cone biopsy, as shown in a large Japanese study of nearly 9,000 patients.¹² These women may need closer follow-up or additional procedures.

Bladder carcinoma in situ behaves differently. It involves flat, high-grade abnormal cells lining the interior of the bladder. After the visible disease is removed through a scope (transurethral resection), patients often receive an immunotherapy agent called Bacillus Calmette-Guérin (BCG), which is instilled directly into the bladder. BCG is the only agent that has been shown to reduce the risk of flat bladder carcinoma in situ progressing to muscle-invasive disease.¹³ Despite having been used for more than four decades, exactly how BCG works against bladder cancer at the cellular level is still not fully understood.¹⁴

Stage 0 in the Colon and Rectum

In colorectal cancer, stage 0 refers to abnormal cells confined to the innermost lining (mucosa) of the colon or rectum. These are often found during routine colonoscopy, either as polyps that turn out to contain carcinoma in situ or as flat lesions with suspicious features. Treatment is almost always endoscopic rather than surgical.

Endoscopic submucosal dissection (ESD) has broadened the range of lesions that can be removed through the scope rather than requiring open or laparoscopic surgery. ESD achieves higher rates of removing the entire lesion in one piece compared with older piecemeal techniques, regardless of lesion size.¹⁵ Japanese guidelines, which pioneered many of these techniques, endorse endoscopic treatment not only for early carcinomas but also for precancerous adenomas.¹⁶ For deeper or harder-to-reach lesions, endoscopic full-thickness resection offers an alternative. These advances mean that many people with stage 0 colorectal cancer avoid major surgery entirely.¹⁷

The Overtreatment Problem

The central tension with stage 0 cancer is that not all of it will progress to invasive disease. Some DCIS, for instance, may sit quietly in a milk duct for decades without ever becoming life-threatening. The screening tools that detect it cannot currently tell the difference between the kind that will progress and the kind that won’t. This creates a situation where some patients undergo surgery, radiation, and years of hormonal therapy for a condition that might never have harmed them.

Population-level data make this concern concrete. As lung cancer screening with low-dose CT scans has expanded in places like Taiwan, researchers have documented rising rates of stage 0 lung cancer diagnoses, raising concerns about overdiagnosis and the unnecessary treatment that follows.¹⁸ The same dynamic played out with breast screening decades earlier: DCIS incidence increased more than 16-fold between the early 1970s and 2005, yet researchers have acknowledged that while some of that rise is explained by increased mammography use, not all of it is.³

This issue has even prompted changes in how certain conditions are named. An international group of pathologists, surgeons, and clinicians reclassified a type of non-invasive thyroid tumor, removing the word “carcinoma” from its name entirely. The goal was to reduce the psychological and clinical consequences of labeling an indolent, non-invasive growth as cancer.¹⁹ Similar conversations are happening around low-risk DCIS, though no formal reclassification has taken hold yet.

Active Surveillance as an Alternative

For selected patients with DCIS, researchers are exploring whether close monitoring without immediate treatment, called active surveillance, can safely substitute for surgery. A computational risk analysis modeled what would happen if carefully chosen DCIS patients were monitored instead of treated right away. The projected differences in breast cancer death were small, particularly for older women: a woman diagnosed at age 70 would face a median difference of only about 0.6 percentage points in 10-year breast-cancer-specific mortality between active surveillance and usual care. For a woman diagnosed at 40, that gap widened to about 2.6 percentage points.²⁰

Put differently, for older patients with other health concerns, the number of women you would need to treat with surgery and radiation to prevent a single breast cancer death was very high. The analysis concluded that active surveillance could be a viable option for carefully selected patients, especially older women and those with significant competing health risks. Clinical trials testing this approach in real patients are ongoing, but results are still years away. Until that evidence arrives, active surveillance for DCIS remains an area of active research rather than standard practice.

Predicting Which Stage 0 Cancers Will Progress

If doctors could reliably identify which stage 0 lesions are dangerous and which are harmless, the overtreatment problem would largely dissolve. That is why biomarker research in this area has intensified. In DCIS, several teams have compared the gene activity in lesions that remained in situ forever (“pure DCIS”) with those where the patient later developed invasive cancer. One study identified a set of genes, including CAMK2N1, whose reduced expression was linked to progression. Using these markers, researchers were able to classify about 29% of pure DCIS patients into a lower-hazard group, while only 3% of patients who later developed invasive cancer fell into that same low-risk category.²¹

Separate research has pointed to additional genes involved in cell invasiveness, including FGF2, GAS1, and SFRP1, which were found to be negatively regulated in later stages of cancer development.²² None of these markers are ready for routine clinical use yet, but they point toward a future where a biopsy could yield not just a diagnosis but a personalized risk estimate. That information could help a woman and her doctor decide between immediate surgery and watchful waiting with far more confidence than they have today.

Long-Term Monitoring After Treatment

Regardless of how stage 0 cancer is treated, follow-up imaging is essential. For DCIS specifically, mammography has proven effective at catching recurrences after breast-conserving surgery with radiation, detecting about 97% of cases. Recurrences typically appeared as calcifications or masses, and they were not always near the original surgical site, reinforcing why whole-breast imaging matters rather than focusing only on the scar area. Reassuringly, over 90% of detected recurrences were early-stage, which means the prognosis remained excellent even when cancer came back.²³

For melanoma in situ, follow-up involves regular skin exams, both self-checks and dermatologist visits, because having one melanoma in situ increases the risk of developing another. Cervical carcinoma in situ requires follow-up Pap smears and HPV testing at regular intervals. Bladder carcinoma in situ demands some of the most intensive surveillance of any stage 0 diagnosis: cystoscopy (a scope inserted into the bladder) is repeated at frequent intervals for years, because bladder CIS has a notable tendency to recur.

The Financial Weight of a Stage 0 Diagnosis

Even though stage 0 cancer is the least advanced form, treatment is not cheap. An analysis of insurance claims found that the average cost allowed by insurers in the first year after a stage 0 breast cancer diagnosis was about $61,000, and roughly $72,000 over 24 months. Those numbers climb steeply at higher stages, but stage 0 costs are still substantial.²⁴ For patients, the out-of-pocket burden can be significant. In a study of over 600 women with stage 0 to III breast cancer, about 28% said that treatment costs influenced their surgical decisions, and at household incomes around $45,000 per year, cost concerns outweighed preferences about breast preservation or appearance. More than a third reported financial burden from their cancer treatment, and 78% had never discussed costs with their care team.²⁵

The type of surgery a woman chooses also affects financial outcomes. Bilateral mastectomy with or without reconstruction was associated with higher debt, more severe financial hardship, and changes to employment compared with breast-conserving surgery. Research into what’s sometimes called “financial toxicity” in early-stage breast cancer is still developing, but the evidence already suggests that surgical approach is a meaningful driver of that burden.²⁶

Disparities in Who Gets Caught Early

Stage 0 is, almost by definition, a product of screening. You generally can’t feel DCIS or see melanoma in situ the way you might notice a larger, more advanced cancer. That means access to screening shapes who benefits from early detection and who doesn’t.

The data on breast cancer are stark. African American women have significantly higher odds of being diagnosed at a late stage compared with white women, and women living in areas with high poverty rates face a similar disadvantage.²⁷ A large study using national cancer registry data found that racial and ethnic minority women were substantially more likely to be uninsured or on Medicaid at the time of their breast cancer diagnosis. After adjusting for socioeconomic factors and insurance status, the gap in late-stage diagnosis narrowed but did not disappear, suggesting that insurance access explains a large part of the disparity but not all of it.²⁸

These disparities mean that the benefits of catching cancer at stage 0 are not evenly distributed. Expanding screening access, reducing cost barriers, and addressing the structural factors that keep some communities from getting timely care would shift more diagnoses toward earlier, more treatable stages.

The Psychological Side of Being Told You Have Cancer

Hearing “you have cancer,” even with the qualifier “stage 0,” is psychologically powerful. Research on breast cancer patients has found that about half report high levels of distress at the time of diagnosis, and those levels remain elevated at six months before beginning to decline around the one-year mark. High distress was significantly associated with anxiety even after accounting for underlying depression, and that link actually grew stronger over time rather than fading.²⁹

This is relevant to the overtreatment debate in a very human way. If a woman is told she has DCIS and is offered active surveillance instead of surgery, the anxiety of living with an untreated “cancer” diagnosis can be as difficult to manage as the treatment itself. The thyroid nomenclature change mentioned earlier was motivated in part by exactly this problem: dropping the word “carcinoma” for a low-risk condition that rarely causes harm. Whether similar language shifts will eventually reach DCIS or other stage 0 diagnoses is an open question, but the psychological toll of the cancer label is a real clinical consideration, not just a semantic one.